Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Common Equity (2016 - 2025)

Rein Therapeutics filings provide 10 years of Common Equity readings, the most recent being $16.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 68.9% year-over-year to $16.9 million, compared with a TTM value of $16.9 million through Dec 2025, down 68.9%, and an annual FY2025 reading of $16.9 million, down 68.9% over the prior year.
  • Common Equity hit $16.9 million in Q4 2025 for Rein Therapeutics, down from $46.2 million in the prior quarter.
  • The five-year high for Common Equity was $101.0 million in Q2 2024, with the low at $11.2 million in Q3 2023.
  • Median Common Equity over the past 5 years was $47.1 million (2025), compared with a mean of $47.9 million.
  • The sharpest move saw Common Equity soared 750.44% in 2024, then crashed 68.9% in 2025.
  • Year by year, Common Equity stood at $43.9 million in 2021, then crashed by 57.58% to $18.6 million in 2022, then soared by 427.83% to $98.3 million in 2023, then tumbled by 44.67% to $54.4 million in 2024, then tumbled by 68.9% to $16.9 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $16.9 million, $46.2 million, and $48.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.